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Abstract [3HlMyristic acid prelabeled LA-N-2 cells were ex- 
posed to varying concentrations of amyloid beta protein (25-35), 
from 20 to 250 ttg/ml, and the activation of phospholipases A and 
D estimated. A progressive increase in phosphatidylethanol for- 
mation, a measure of phospholipase D activity, and of free fatty 
acid release, a measure of phospholipase A activity, was observed 
over a time-course of 60 rain. [3H]Inositol prelabeled LA-N-2 
cells were exposed to varying concentrations of AI~ P, from 20 to 
125/xg/ml, and phospholipase C activation was measured. There 
was an increased release of inositol phosphates in the presence of 
amyloid beta protein as a function of incubation time. The effects 
of adrenergic, metabotropic amino acid and bombesin antagonists 
on the A~I P mediated stimulation of phospholipase C activity was 
investigated. Propranolol, a ~ adrenergic antagonist, 7-chloro- 
kynurenic acid, a metabotropic amino acid antagonist, and [Tyr 4- 
D-Phe~2]bombesin, a bombesin antagonist, blunted the A~I P stim- 
ulation of phospholipase C activity in [3H]inositol prelabeled LA- 
N-2 cells. This suggests that amyloid beta protein activation of 
phospholipase C may be receptor mediated. The phospholipase 
C inhibitor U 71322 prevented the activation of phospholipase C
by Ai~I P. However, this activation was not effeeted by tocopherol, 
propylgallate, or vitamin C. 
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1. Introduction 
The neuropatholigical h llmark of Alzheimer's disease (AD) 
is the abundance and pattern of distribution of senile plaques 
and neurofibrillary tangels [1]. The predominant protein pres- 
ent in these structures i amyloid beta protein (AflP) having a 
4042 amino acid chain length [2]. The possible contribution of
AflP to the neuronal degeneration characteristic of AD is 
largely based upon experimental evidence obtained both from 
in vitro and in vivo observations. The presence of AflP at the 
time of hippocampal cell seeding increased the numbers of cells 
during the first 2 days, suggesting a neurotropic effect, but 
decreased the numbers of cells at longer times of exposure [3]. 
The neurotoxicity of AflP or its truncated form containing 
amino acids 25 35 has been observed in vivo [4] and in vitro 
[5] and there are reported neurotoxic effects by intracerebral 
injections of AflPI --* 40 [6, 7]. A possible xplanation for this 
duality of neurotropic and neurotoxic properties may be related 
to the state of AflP aggregation. Freshly prepared solutions of 
AflP do not possess neurotoxic properties but 'aged' prepara- 
tions which contain aggregates are neurotoxic to cell cultures 
[5, 8]. AflP-generated free radicals and/or lipid peroxides may 
contribute to this neurotoxicity [9 11]: this was prevented by 
several antioxidants [11, 12]. 
The AflP neurotoxicity seen with cultured human fetal corti- 
cal cells was not prevented by the classical excitatory amino 
antagonists kynurenate or20-amino-5-phosphonovalerate [13]. 
This suggests that excitatory amino acids or their receptors are 
not involved in AflP-provoked neurotoxicity. We wish to report 
that AflP (25 35) stimulates phospholipase A, C and D activi- 
ties of the human neuroblastoma LA-N-2 cells. 
2. Materials and methods 
2.1. Materials 
[9,10-3H]Myristic a id (39.3 Ci/mmol) and myo-[2-3H]inositol (17.6 
Ci/mmol) were purchased from Dupont-NEN, Boston, MA. AflP (25- 
35), propylgallate, ocopherol and L-ascorbic acid were purchased from 
Sigma Chemicals, St. Louis, MO, and Bachem California, Torrance, 
CA. L-Norepinephrine bitartrate, trans-l-aminocyclopentyl-l,2-dicar- 
boxylic acid (ACPD), propranolol-HCL, 7-chlorokynurenic acid and 
U 73122 were obtained from Research Biochemicals International, 
Natick, MA, USA. Bombesin and [Tyra-o-Phel2]bombesin were ob- 
tained from Sigma Chemicals, St. Louis, MO, USA. Liebovitzs' L-15 
medium and heat inactivated fetal calf serum were from Flow Labora- 
tories, Mississauga, Ont. Silica gel G60 TLC plates were from Merck 
Darmstadt, Germany. Phosphatidylethanol standard was prepared as 
previously described [14]. The human euroblastoma cell line, LA-N-2 
(passage 81) was obtained from Dr. R. Seeger, UCLA, and maintained 
as previously described [15]. 
2.2. Cell prelabeling and analytical proce&4res 
The cell labeling with [3H]myristic a id, lipid extraction and the thin 
layer chromatographic procedures mployed for measurement of phos- 
pholipase A (PLA) and D (PLD) activities were as previously described 
[16]. Confluent monolayer cultures of LA-N-2 cells were incubated with 
2 pCi/ml myo-[3H]inositol f r 48 h in L-15 medium containing 15% fetal 
bovine serum to label the phosphatidylinositols. Thecells were har- 
vested, washed twice with L-15 medium containing 10 mM lithium 
chloride (LiC1), and these [3H]inositol prelabeled cells were incubated 
in 1.0 ml L-15 medium containing 10 mM LiCI with the various agonists 
and antagonists as described, and the reactions were terminated by 
adding 200/.tl of ice-cold 50% trichloroacetic a id (TCA). Samples were 
transferred into Eppendorf centrifuge tubes, kept on ice for 15 min, 
were centrifuged and the TCA extracts transferred into 13 × 100 mm 
glass tubes. The TCA extracts were washed five times with diethylether 
(1:1 ratio) and the pH of these samples adjusted to neutral with 1 M 
NaOH. The extracts were applied to Dowex-I formate columns, and 
the labeled inositol phosphates were eluted as described [17]. 
3. Results 
*Corresponding author. 
Abbreviations: AflP, amyloid beta protein; PLA, phospholipase A;
PLC, phospholipase C; PLD, phospholipase D; AD, Alzheimer's dis- 
ease; PtdETOH, phosphatidylethanol; FFA, free fatty acid. 
3.1. A[JP dose reponses 
[3H]Myristic acid or [3H]inositol prelabeled LA-N-2 cells 
were exposed to varying concentrations of AflP. There was a 
progressive increase in free fatty acid release, ameasure of PLA 
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Fig. I. Activation of phospholipases A, C and D of cultured LA-N-2 
cells by increasing amounts of AflP. The final concentrations offreshly 
prepared AflP are as indicated. The activations of PLD (panel A) and 
PLA (panel B) were determined with [3H]myristic acid-prelabeled cul- 
tures. The appearance of the radioactive inositol phosphates from 
[3H]inositol-prelabeled c lls was regarded as a measure of PLC activa- 
tion (Panel C). 
activity (Fig. 1B) with increasing quantities of AflP present. The 
amount of PtdETOH, a measure of PLD activity, increased 
linearly with 20-80/.tg AflP/ml and appeared to plateau (Fig. 
1A). Inositol monophosphate was the major product of PLC 
activation and the quantity increased with 20-125/lg AflP/ml 
to reach a plateau (Fig. 1C). 
3.2. Time-course 
There was an increase in the appearance of the total inositol 
phosphates with the duration of exposure to AflP and a plateau 
was reached by 5 min (Fig. 2B). There was a progressive in- 
crease in PtdETOH formation over the complete time-course 
of 60 min (Fig. 2A). Free fatty acid release reached a plateau 
by 15 min of exposure to AflP (Fig. 2A). 
3.3. 'Aged' A~P 
'Aged' AflP was produced by incubation of sterile aquaous 
solutions at 37°C for 7 days [5] and the ability to activate the 
phospholipases determined. 'Aged' AflP (25-35) at 125/.tg/ml 
was capable of activating PLA 2.2 fold, PLC 1.8 fold and PLD 
3.3 fold. 
3.4. PLC activity and receptors 
We have previously reported that LA-N-2 cellls have both 
metabotropic and adrenergic receptors coupled to PLC [18] but 
not to PLA or PLD. Exposure of the inositol prelabeled cells 
to bombesin results in an increased release if inositol phos- 
phates. Maximum PLC activation occured with 100 nM bomb- 
esin and this was blunted by 10/IM [Tyra-D-Phe~2]bombesin, its 
antagonist [19] (Table 1). We investigated the possibility that 
metabotropic, adrenergic and bombesin receptor occupancy 
may be involved in the stimulation of PLC activity by 'fresh' 
and 'aged' AflP. Preincubation of [3H]inositol labeled LA-N-2 
cells with either 50 /2M propranolol or 50 ~tM 7-chloro- 
kynurenic acid or 25/.tM [Tyr4-D-Phe'2]bombesin for 15 min 
blunted the formation of inositol phosphates provoked by sub- 
sequent exposure in these cells to 'fresh' AflP (Table 2). 
3.5. Antioxidants and a PLC &hibitor 
U 73122 is a PLC inhibitor and prevents the ligand-stimu- 
lated inositol phosphate increase in human neuroblastoma cells 
[20] pancreatic acinal cells [21] and NG108-15 cells [22]. The 
presence of 2 ,uM U 73122 completely suppressed the AflP 
stimulation of PLC activity. In contrast the presence of 250/~M 
tocopherol, 25/2M propylgallate or 300 HM-L-ascorbic acid 
did not effect this AflP stimulation. (data not shown). 
4. Discussion 
AflP (25 35) activates the phospholipases A, C and D of 
LA-N-2 cells in a dose- and time-dependent manner (Figs. 1 and 
2). Previous attempts to relate AflP effects to a particular recep- 
tor type have been either unsuccessful or inconclusive. Indeed 
there is no consensus currently available supporting the possi- 
bility that the cellular responses to AflP are dependent upon 
receptor occupancy. A possible mechanism contributing to the 
neurotoxic effects of AflP focused upon calcium homeostasis 
[23]. Exposure of hippocampal cultures to aggregated AflP 
caused elevations in intracellular calcium [24]. The neurodegen- 
eration of primary cortical neuronal cultures exposed to AflP 
was prevented by the presence of nimodipine, a calcium chan- 
nel blocker, supporting a possible role for calcium in the AflP 
neurotoxicity [25]. The neurotoxicity ofAflP toward hippocam- 
pal cultures was not prevented by several voltage- or ligand- 
gated blockers [26] employing different culture conditions than 
by others [25]. Elevated internal calcium levels could be respon- 
sible for the phospholipase A and D activations since these are 
calcium-dependent zymes [27]. 
The pretreatment of inositol-prelabeled LA-N-2 cells with 
propranolol or 7-chlorokynurenic acid or [Tyr4-D-Phel2]- 
Table 1 
Activation of phospholipase C (PLC) by bombesin and prevention by 
4 12 a [Tyr-D-Phe ]bombesin 
Total inositol phosphates b 
Control 388,399 + 87,902 
Bombesin (100 nM) 1,173,770 +420,599 c 
[Tyr4-D-Phel2]bombesin (10/tM) 229,343 + 23,563 
Bombesin (100 nM) + 301,166 + 49,160 
[Tyra-D-PheJ2]bombesin (10/.tM) 
Representative of 3 separate experiments performed in triplicate. 
b Expressed as DPM's/mg protein/10 min. 
c p < 0.01 vs. controls. 
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bombesin blunted the PLC activation provoked by AflP (Table 
2). Thus, these studies uggest hat AflP stimulation of PLC 
activity may be mediated through adrenergic, metabotropic 
and bombesin-type r ceptors. The prevention of AflP activa- 
tion of PLC by U 73122 was anticipated since this compound 
inhibits PLC activation by a number of agonists in a number 
of cell types. The inability of the antioxidants, tocopherol, pro- 
pylgallate and vitamin C, to blunt the AflP activation of PLC 
indicates that this activation is not mediated by free radical 
formation. 
Increased quantities of free myo-inositol have been detected 
by 'H NMRS in vivo [28] and in perchloric acid extracts of 
autopsy [29] tissues from Alzheimer's disease patients• It is 
possible that this elevation of inositol might be a reflection of 
increased PLC activation in Alzheimer's disease. There are no 
detectable quantitative differences in PLC activity of mem- 
branes derived from Alzheimer's patients as compared to con- 
trols [30,31], however, responsiveness in vitro to agonists or the 
preponderance of a particular PLC isoform are altered. Per- 
haps the increased myo-inositol bserved in the brain tissue of 
Alzheimer's disease individuals is a consequence of the AflP 
activation of PLC. The excessive quantities of AflP in proximity 
to the cell surface could activate phospholipases and, therefore, 
trigger second messenger cascades which would provoke an 
unnecessary cellular esponse. Continuous aberrant activation 
could be deleterious to neurons and ultimately lead to the 
neuronal loss seen in Alzheimer's disease. 
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Table 2 
The effect offl adrenergic, metabotropic and bombesin antagonists on 
PLC stimulation by 'fresh' and 'aged' ABP (25-35) 
Treatment Total inositol phosphates a 
A. Fresh 
Control 311,149 + 39,067 
ABP (125/tg/ml) 764,194 + 116,873 b (146% c)
ABP (125/zg/ml) +50 gM 296,465 + 53,415 
propranolol 
ABP (125 gg/ml) + 50 gM 272,293 _+ 64,842 
7-chlorokynurenic acid 
ABP (125/.tg/ml) + 25/IM 272,533 + 9,975 
[Tyr4-D-Phe 12] bombesin 
B. Aged 
Control 165,129 + 21,252 
A~P (250 ,ug/ml) 317,407 + 78,821 d (92%) 
ABP (250 ,ug/ml) + 500 gM 212,206 _+ 62,173" (29%) 
propranolol-treated c lls 
ABP (250/.tg/ml) + 500 gM 7- 180,018 + 41,964 f (10%) 
chlorokynurenic a id-treated cells 
ABP (250 gg/ml) + 250 gM 212,992 + 28,192 e (28%) 
[Tyra-o-Phe'2]bombesin-treated 
cells 
All values are the average + S.D. for independent experiments, each 
conducted in triplicates. 
a Expressed as DPM's/mg protein/10 min. 
bp < 0.001 VS. control cells. 
c Values in parenthesis are percentage increases compared to controls. 
d p < 0.005 vs. control cells. 
P < 0.025 vs. control cells. 
r Not significantly different. 
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Fig. 2. Time-course of the activation of PLC (panel B) PLA (panel A) 
and PLD (panel A) by ABE The concentration f ABP was 125/tg/ml 
for both the [3H]inositol- and the [3H]myristate-prelabeled c ls.
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